ReviewFrontiers in cell and developmental biology2021
Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mesenchymal stem cell therapy and gut microbiota modulation in preclinical disease models: a systematic review with implications for hypertension.Molecular biology reports · 2026Pooled it
- Enhancing the Scalable Manufacturing of Human Mesenchymal Stromal Cells in Dynamic Culture Using Bioactive Heparin/Collagen Layer-by-Layer Coated Microcarriers.Biotechnology journal · 2026Article
- ROS-Responsive Eye Drop for Controlled Release of 20-Deoxyingenol Improves Diabetic Corneal Healing by Activating Macrophage Autophagy and Metabolic Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Bone marrow-derived mesenchymal stem cells for ischemic stroke: mechanisms, delivery strategies, clinical evidence, and translational challenges.Stem cell research & therapy · 2026Review
- Design Strategies to Target Joint Resident Mesenchymal Stem Cells for Osteochondral Regeneration.Cells · 2026Review
- Translating potential into practice: the evolving landscape of neural stem cell therapeutics in clinical applications.Annals of medicine and surgery (2012) · 2026Review
- The Promise and Challenges of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Periodontal Disease.Pathogens (Basel, Switzerland) · 2026Review
- Characteristics of the Stem Cell Intellectual Property Rights and Patent Status: Focusing on Papers and Clinical Trials.Development & reproduction · 2026Article
- Cell-free therapeutics for non-healing wounds: role of MSC-derived exosomes in macrophage polarization, angiogenesis, and fibroblast-mediated ECM remodeling-bridging preclinical insights to clinical translation.Inflammopharmacology · 2026Review
- Musculoskeletal ultrasound-guided cellular therapy: Current applications and future directions in skeletal muscle regeneration.Iranian journal of basic medical sciences · 2026Review
- Mesenchymal stem cell and exosome-based therapies for degenerative disc disease: from mechanisms to clinical translation.Frontiers in cell and developmental biology · 2026Review
- Functionalized mesenchymal stem cells for enhanced bone regeneration: advances and challenges.Stem cell research & therapy · 2025Review
- Emerging insights into mesenchymal stem cells and exosome-based therapies for liver injury.Biomolecules & biomedicine · 2025Review
- Upstream Process Protocol for MSCs Isolated from Different Human-Based Tissue Origins.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Optimization of Culture Media for Human Umbilical Cord-Derived Mesenchymal Stem Cell Production.Stem cells international · 2025Article
- Article
- Definition of Synovial Mesenchymal Stem Cells for Meniscus Regeneration by the Mechanism of Action and General Amp1200 Gene Expression.International journal of molecular sciences · 2024Article
- Emerging Landscape ofACS pharmacology & translational science · 2024Review
- A GMP-compliant manufacturing method for Wharton's jelly-derived mesenchymal stromal cells.Stem cell research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human mesenchymal stromal cell (hMSC) therapy has been gaining immense interest in regenerative medicine and quite recently for its immunomodulatory properties in COVID-19 treatment. Currently, the use of hMSCs for various diseases is being investigated in >900 clinical trials. Despite the huge effort, setting up consistent and robust scalable manufacturing to meet regulatory compliance across various global regions remains a nagging challenge. This is in part due to a lack of definitive consensus for quality control checkpoint assays starting from cell isolation to expansion and final release criterion of clinical grade hMSCs. In this review, we highlight the bottlenecks associated with hMSC-based therapies and propose solutions for consistent GMP manufacturing of hMSCs starting from raw materials selection, closed and modular systems of manufacturing, characterization, functional testing, quality control, and safety testing for release criteria. We also discuss the standard regulatory compliances adopted by current clinical trials to broaden our view on the expectations across different jurisdictions worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.